The Cannabinoid Research Group of Complutense University in Madrid, Spain and Voices Against Brain Cancer, a U.S. foundation headquartered in New York, on Monday announced that a collaborative medical marijuana research alliance has been signed by both organizations.
The consideration of the benefits of marijuana and the compounds contained within the plant known as "cannabinoids" for medicinal purposes is currently a prominent subject matter in North America. In an effort to fast-track the propagation of accurate scientific based information on therapeutic opportunities incorporating cannabinoids, these two groups have formed an exclusive partnership in the United States.
"We have chosen Voices Against Brain Cancer to act as our voice in North America where they will support and herald our efforts," said Manuel Guzmán, chairman of The Cannabinoid Research Group. When asked about the research findings to date, Guzman noted that "published research clearly shows the anticancer action of cannabinoids impacting glioblastoma multiforma (GBM), and how chemotherapy results of tumor reduction are improved upon by adding cannabinoids as part of the treatment regimen."
"We have an obligation to remain open minded about where the cure for brain cancer will come from," said Michael Klipper, chairman of Voices Against Brain Cancer. "Manuel Guzmán and his research team are world class leaders in the clinical research of cannabinoids and cancer."